Sulbactam-Durlobactam for Treatment of Bacterial Pneumonia.

The article focuses on a randomized clinical trial evaluating sulbactam-durlobactam's non-inferiority to colistin in treating serious bacterial infections caused by Acinetobacter baumannii-calcoaceticus complex organisms. Topics include the study's methodology, the primary endpoint of 28-day all-cause mortality, and the approval of sulbactam-durlobactam by the Food and Drug Administration for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.